WO2005107694A1 - Topical cypress essential oil composition for stretch marks - Google Patents
Topical cypress essential oil composition for stretch marks Download PDFInfo
- Publication number
- WO2005107694A1 WO2005107694A1 PCT/AU2005/000655 AU2005000655W WO2005107694A1 WO 2005107694 A1 WO2005107694 A1 WO 2005107694A1 AU 2005000655 W AU2005000655 W AU 2005000655W WO 2005107694 A1 WO2005107694 A1 WO 2005107694A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- topically applied
- composition according
- vol
- lesions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Definitions
- the present invention relates to a topically applied composition, in particular to a topically applied composition for treatment of striae distensae lesions, also known as stretch marks .
- Striae distensae lesions typically occur on the abdomen, breasts, buttocks, hips, and thighs. They are thought to arise due to weakening of the elastic skin tissues during pregnancy, rapid growth spurts in adolescence, and periods of excessive weight change. Their appearance can also be associated with topical or prolonged treatment with corticosteroids .
- striae distensae lesions are not regarded as a medical problem, their cosmetic appearance can cause considerable distress, particularly if the affected area is widespread. Furthermore, to date there has been no known treatment that minimises or reduces their appearance although the appearance of the lesions does become less pronounced over prolonged periods of time.
- the present invention seeks to overcome or at least alleviate striae distensae lesions and/or their appearance.
- the invention features a topically applied composition for treatment of striae distensae lesions, the composition comprising a pharmaceutically or cosmetically acceptable vehicle for topical application and an effective amount of cypress essential oil.
- the cypress essential oil is present in an amount up to 5% by volume, preferably between 1.0 - 4.0 % by volume.
- the pharmaceutically or cosmetically acceptable vehicle comprises a carrier oil .
- carrier oils include, but are not limited to, sweet almond oil, olive oil, wheat germ oil, castor oil, avocado oil, rosehip seed oil, calendula oil, jojoba oil, grape seed oil, apricot kernel oil, flaxseed oil, hazelnut oil, walnut oil, pecan nut oil, macadamia nut oil, and vegetable oils such as for example safflower oil, sunflower oil, canola oil, soybean oil, and peanut oil, and combinations thereof .
- the preferred carrier oil is a mixture of sweet almond oil, wheat germ oil, olive oil, and castor oil.
- the topically applied composition comprises sweet almond oil, wheat germ oil, olive oil, castor oil, and cypress essential oil.
- the topically applied composition comprises sweet almond oil in the range of 20 - 60 %v/v, wheat germ oil in the range of 20 - 55 %v/v, olive oil in the range of 15 - 45 %v/v, castor oil in the range of 2 - 10 %v/v, and cypress essential oil in the range of up to 5 %v/v, with the balance of the composition at 100%.
- the pharmaceutically or cosmetically acceptable vehicles comprise lotions, creams, ointments, gels, and solid formulations such as for example a wax-based stick.
- the composition further comprises other pharmaceutically active agents in addition to cypress essential oil, provided that they do not detrimentally affect the desired effect on the treated area afforded by the cypress essential oil .
- the invention features a method of treating striae distensae lesions to improve the appearance thereof comprising topically applying to an area affected by the lesions a composition comprising a pharmaceutically or cosmetically acceptable vehicle for topical treatment and an effective amount of cypress essential oil.
- the composition is topically applied to an area affected by striae distensae lesions at least once a week, preferably once or twice a day.
- the composition is topically applied to the affected area until the appearance of the striae distensae lesions has been improved, reduced, or minimi ed to the satisfaction of the user.
- the invention features a method of improving the appearance of the striae distensae lesions comprising topically applying to an area affected by the lesions a composition comprising a pharmaceutically or cosmetically acceptable vehicle for topical treatment and an effective amount of cypress essential oil.
- the invention features a topically applied composition when used to prepare a dermopharmaceutical or cosmetic to improve the appearance of the striae distensae lesions, the topically applied composition comprising a pharmaceutically or cosmetically acceptable vehicle for topical treatment and an effective amount of cypress essential oil.
- compositions of the present invention are prepared by mixing the cypress essential oil and, optionally, other pharmaceutically active agents with the pharmaceutically or cosmetically acceptable vehicle.
- a topically applied composition for treatment of striae distensae lesions to improve the appearance thereof is provided.
- topically applied topically applying
- topical application refers to directly - b
- an applicator such as a wipe or a cotton swab, or by hand.
- the colour of the lesions changes from an inflamed reddish appearance to pink, through to a pale skin tone colour, and/or the width and/or the depth of the lesions narrows such that the appearance of the lesions in the affected area becomes less pronounced than before the treatment period, during which treatment period the composition of the present invention is regularly applied to an affected area, commenced.
- the topically applied composition comprises a pharmaceutically or cosmetically acceptable vehicle for topical treatment and an effective amount of cypress essential oil .
- Cypress essential oil is derived from Cupressus semperivirens, typically by steam distillation of the needles thereof.
- the cypress essential oil is present in the composition in an amount up to 5% by volume, preferably between 1.0 - 4.0% by volume.
- the upper limit envisaged for the maximum amount of cypress essential oil in the topically applied composition is limited by the appearance of toxic effects associated with cypress essential oil, which are thought to manifest at concentrations of cypress essential oil of >10% by volume.
- pharmaceutically or cosmetically acceptable refers to pharmaceutically active agents or inert ingredients which are suitable for use in contact with the skin without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
- an effective amount refers to an amount of composition sufficient to significantly induce an improvement in the appearance of the striae distensae lesions of the affected area that is treated, but low enough to avoid serious side effects.
- the effective amount of the composition will vary with the age and physical condition of the patient in need of treatment, the extent of the area that requires treatment, the severity of the striae distensae lesions, the duration of the treatment, the particular pharmaceutically or cosmetically acceptable vehicle used, and like factors.
- the pharmaceutically or cosmetically acceptable vehicle comprises at least 95% volume of the topically applied composition of the present invention.
- the pharmaceutically or cosmetically acceptable vehicle comprises a carrier oil.
- carrier oils include, but are not limited to, sweet almond oil, olive oil, wheat germ oil, castor oil, avocado oil, rosehip seed oil, calendula oil, jojoba oil, grape seed oil, apricot kernel oil, flaxseed oil, hazelnut oil, walnut oil, pecan nut oil, macadamia nut oil, and vegetable oils such as for example safflower oil, sunflower oil, canola oil, soybean oil, and peanut oil, and combinations thereof .
- the preferred carrier oil is a mixture of sweet almond oil, wheat germ oil, olive oil, castor oil, such that the topically applied composition comprises sweet almond oil, wheat germ oil, olive oil, castor oil, and cypress essential oil.
- the topically applied composition comprises sweet almond oil in the range of 20 - 60 %v/v, wheat germ oil in the range of 20 - 55 %v/v, olive oil in the range of 15 - 45 %v/v, castor oil in the range of 2 - 10 %v/v, and cypress essential oil in the range of up to 5 %v/v, with the balance of the composition at 100%.
- the components of the preferred carrier oil afford additional therapeutic benefits to the patient treated with the preferred embodiment of the present invention.
- Sweet almond oil, olive oil, castor oil and wheat germ oil are readily absorbed by the skin, thereby transporting the cypress essential oil to sub-cutaneous layers of the dermis to effect its therapeutic effect on the affected area.
- olive oil, sweet almond oil and wheat germ oil are emollients.
- Castor oil is alleged to have anti-microbial properties and wheat germ oil is rich in vitamins A, Bl and B2, D and E.
- compositions are lotions, creams, ointments, gels, and solid formulations such as for example a wax-based stick.
- Other pharmaceutically or cosmetically acceptable vehicles can be formulated by those of ordinary skill in the art.
- the composition further comprises other pharmaceutically active agents in addition to cypress essential oil, provided that they do not detrimentally affect the desired effect on the treated area afforded composition.
- pharmaceutically active agent refers to a compound that has a cosmetic or therapeutic effect on the skin, for example, vitamins, antioxidants , essential oils, botanical or animal extracts, anti-microbial agents, and the like, and combinations thereof.
- vitamins include, but are not limited to, vitamin A, vitamin Bs such as vitamin B3 , vitamin B5, and vitamin B12, vitamin C, vitamin K, and vitamin E and derivatives thereof.
- essential oils include, but are not limited to, bergamot, clary sage, lavender, juniper, pine, marjoram, sandalwood, rosemary, frankincense, and citrus oils.
- compositions of the present invention can contain conventional cosmetic additives, such as for example colourants and fragrances.
- topically applied compositions of the present invention can contain preservatives, hu ectants, anti- microbial agents and the like to stabilize the topically applied composition and prolong its shelf life.
- the cypress essential oil and, optionally, other pharmaceutically active agents are mixed with the pharmaceutically or cosmetically acceptable vehicle.
- the pharmaceutically or cosmetically acceptable vehicle acts as a diluent or carrier for other materials present in the composition, so as to facilitate their distribution and delivery to the affected area which requires treatment.
- the composition is topically applied to an area affected by striae distensae lesions at least once a week, such as once or twice a day. In one embodiment, the composition is topically applied to the affected area until the appearance of the striae distensae lesions has been improved, reduced, or minimized to the satisfaction of the user.
- the composition is topically applied to the affected area twice daily for the first two weeks of treatment and then once daily, although a twice daily application or intermittent application every few days may provide satisfactory results in some cases.
- Clinically significant improvement in the appearance of the lesions is generally observed after three to six weeks of daily treatment, wherein the size and colour of the lesions are substantially reduced.
- the following examples illustrate, but do not limit, the invention by detailing a preferred embodiment and the efficacy of the same in treating striae distensae lesions.
- composition was topically applied once daily to an extensive abdominal area of a post-natal woman exhibiting striae distensae lesions, resulting in a marked improvement (estimated at 95%) in the appearance of the lesions in three weeks.
- the first composition was topically applied once or twice daily to an extensive abdominal area of a post-natal woman exhibiting striae distensae lesions for a period of ten (10) days, and then the affected area was treated with once or twice daily topical applications of the second composition for a further period of 3-4 weeks, resulting in a marked improvement (estimated at 95%) in the appearance of the lesions after completion of the above treatment.
- composition was topically applied intermittently to an extensive area covering the abdomen and buttocks of a post-natal woman exhibiting striae distensae lesions, resulting in a marked improvement (estimated at 80%) in the appearance of the lesions.
- composition was topically applied once daily to an extensive lumbo- sacral area of an adolescent male exhibiting striae distensae lesions, resulting in an improvement (estimated at 60-70%) in the appearance of the lesions in three weeks.
- compositions may also be used in accordance with a preferred embodiment of the present invention.
- compositions falling within the ranges outlined below are envisaged to be topically applied to males or females who exhibit striae distensae lesions in accordance with the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007511770A JP2007537165A (en) | 2004-05-11 | 2005-05-09 | Topical cypress essential oil composition for stretch marks |
US11/579,973 US20080020075A1 (en) | 2004-05-11 | 2005-05-09 | Topical Cypress Essential Oil Composition for Stretch Marks |
AU2005239762A AU2005239762B2 (en) | 2004-05-11 | 2005-05-09 | Topical cypress essential oil composition for stretch marks |
EP05738263A EP1750660A1 (en) | 2004-05-11 | 2005-05-09 | Topical cypress essential oil composition for stretch marks |
IL178985A IL178985A0 (en) | 2004-05-11 | 2006-11-01 | Topical cypress essential oil composition for stretch marks |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004902458 | 2004-05-11 | ||
AU2004902458A AU2004902458A0 (en) | 2004-05-11 | Topically applied composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005107694A1 true WO2005107694A1 (en) | 2005-11-17 |
Family
ID=35320015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2005/000655 WO2005107694A1 (en) | 2004-05-11 | 2005-05-09 | Topical cypress essential oil composition for stretch marks |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080020075A1 (en) |
EP (1) | EP1750660A1 (en) |
JP (1) | JP2007537165A (en) |
KR (1) | KR20070007916A (en) |
CN (1) | CN1953732A (en) |
IL (1) | IL178985A0 (en) |
MY (1) | MY150890A (en) |
WO (1) | WO2005107694A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2316207A1 (en) * | 2007-05-09 | 2009-04-01 | Eva Maria Zomeño Alarcon | Body oil. (Machine-translation by Google Translate, not legally binding) |
EP3977979A1 (en) * | 2020-10-02 | 2022-04-06 | Tej Lalvani | Natural therapy for prevention of early stretch mark development |
EP3787654A4 (en) * | 2018-05-02 | 2022-04-20 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Topical compositions for stretch marks on the skin |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109745253B (en) * | 2017-11-03 | 2021-11-09 | 陕西慧康生物科技有限责任公司 | Composition for removing striae atrophicae |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2631824A1 (en) * | 1988-05-31 | 1989-12-01 | Fourreau Jacques | Cosmetic skin care compositions of the face-pack and antiwrinkle cream type |
FR2659556A1 (en) * | 1990-03-15 | 1991-09-20 | Mu Laboratoire Eurl | Compositions based on arnica and their uses, in particular in pharmaceutical or cosmetic compositions |
WO1994023732A1 (en) * | 1993-04-08 | 1994-10-27 | Kambourakis Medicinal Solutions Pty. Limited | Therapeutic preparations containing cypress tree extracts and methods of using same |
US20030206973A1 (en) * | 2002-05-01 | 2003-11-06 | Carolyn Gale | All natural gentle deodorant and antiperspirant |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2787322B1 (en) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | OIL-IN-WATER EMULSION COMPRISING A MICRONIZED ACTIVE AGENT AND AN APPROPRIATE EMULSION SYSTEM |
US20040161435A1 (en) * | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
-
2005
- 2005-05-09 WO PCT/AU2005/000655 patent/WO2005107694A1/en active Application Filing
- 2005-05-09 EP EP05738263A patent/EP1750660A1/en not_active Withdrawn
- 2005-05-09 CN CNA2005800150737A patent/CN1953732A/en active Pending
- 2005-05-09 KR KR1020067023391A patent/KR20070007916A/en not_active Application Discontinuation
- 2005-05-09 JP JP2007511770A patent/JP2007537165A/en active Pending
- 2005-05-09 US US11/579,973 patent/US20080020075A1/en not_active Abandoned
- 2005-05-11 MY MYPI20052128 patent/MY150890A/en unknown
-
2006
- 2006-11-01 IL IL178985A patent/IL178985A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2631824A1 (en) * | 1988-05-31 | 1989-12-01 | Fourreau Jacques | Cosmetic skin care compositions of the face-pack and antiwrinkle cream type |
FR2659556A1 (en) * | 1990-03-15 | 1991-09-20 | Mu Laboratoire Eurl | Compositions based on arnica and their uses, in particular in pharmaceutical or cosmetic compositions |
WO1994023732A1 (en) * | 1993-04-08 | 1994-10-27 | Kambourakis Medicinal Solutions Pty. Limited | Therapeutic preparations containing cypress tree extracts and methods of using same |
US20030206973A1 (en) * | 2002-05-01 | 2003-11-06 | Carolyn Gale | All natural gentle deodorant and antiperspirant |
Non-Patent Citations (1)
Title |
---|
"Cel-lite magic massage oil", XP008114963, Retrieved from the Internet <URL:http://heavenscentoils.net/massage.oils.htm> [retrieved on 20050704] * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2316207A1 (en) * | 2007-05-09 | 2009-04-01 | Eva Maria Zomeño Alarcon | Body oil. (Machine-translation by Google Translate, not legally binding) |
EP3787654A4 (en) * | 2018-05-02 | 2022-04-20 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Topical compositions for stretch marks on the skin |
EP3977979A1 (en) * | 2020-10-02 | 2022-04-06 | Tej Lalvani | Natural therapy for prevention of early stretch mark development |
Also Published As
Publication number | Publication date |
---|---|
CN1953732A (en) | 2007-04-25 |
MY150890A (en) | 2014-03-14 |
KR20070007916A (en) | 2007-01-16 |
EP1750660A1 (en) | 2007-02-14 |
JP2007537165A (en) | 2007-12-20 |
US20080020075A1 (en) | 2008-01-24 |
IL178985A0 (en) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101420599B1 (en) | Compositions containing anti-acne agents and the use thereof | |
JP2001500841A (en) | Cosmetic and cosmetic compositions for tightening and smoothing the skin in the case of impaired subcutaneous connective adipose tissue, especially fatty edema | |
US20050100524A1 (en) | Skin formulation | |
US20060088497A1 (en) | Topical skin care composition | |
JP6781358B1 (en) | Foamable topical composition | |
JP2008502659A (en) | Use of a pharmaceutical composition comprising clobetasol propionate and calcitriol for the treatment of psoriasis | |
US20080020075A1 (en) | Topical Cypress Essential Oil Composition for Stretch Marks | |
CN110769817A (en) | Skin treatment method, retinoid-containing composition and delivery system thereof | |
WO2007132273A2 (en) | Rinse-off therapeutic agents for treating skin | |
JP7443001B2 (en) | Retinol oil composition | |
AU2005239762B2 (en) | Topical cypress essential oil composition for stretch marks | |
US20200030398A1 (en) | Skin care composition | |
JP5063072B2 (en) | Skin external composition | |
KR20210031078A (en) | Cream type Cosmetic Composition for Cleansing comprising High content of Oil phase and Preparation Method thereof | |
JP2002161018A (en) | Cosmetic | |
US9999588B1 (en) | Topical skin care formulations and methods of using same | |
WO2022131079A1 (en) | Topical composition | |
AU2011242139B2 (en) | Compositions containing anti-acne agents and the use thereof | |
WO2012146926A1 (en) | Tacky cosmetic formulation | |
JP2022067968A (en) | External composition | |
JPS61254525A (en) | Remedy for pimple blended with 11alpha-hydroxy-progesterone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 178985 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11579973 Country of ref document: US Ref document number: 1020067023391 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007511770 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580015073.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006502264 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005239762 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005738263 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3716/KOLNP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005239762 Country of ref document: AU Date of ref document: 20050509 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005239762 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067023391 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005738263 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11579973 Country of ref document: US |